IFN for Renal Cell Cancer: Impact of Dose | Federal Practitioner

FULL MENU FULL MENU
- MDedge Home
- Diseases & Conditions
  - Depression
  - Diabetes
  - Hepatitis
  - HIV
  - Long COVID
  - Obesity
  - Pain
  - PTSD
  - Stroke
  - Traumatic Brain Injury
- Hematology and Oncology
- Specialties
- Federal News
- Original Articles
  - Case Reports
  - Original Research
- Reviews
  - Best Practices
  - Clinical Review
- Perspectives
  - Commentary
  - Q&A
- Diversity in Medicine
Explore
- Multimedia
  Explore
  Audio
  
  Video
  
  Blood & Cancer podcast
  
  Dermatology Weekly podcast
  
  Psychcast podcast
  
  All MDedge podcasts
- News
  Explore
  News by Conference
- Expert Interview
- For Residents
- Quizzes
  Explore
  MD-IQ
- CME Supplements
- ReCAP
- Conference ReCAP
- Supplements
- Sponsored Content
  Explore
  
  Treatment of Veterans With Metastatic Hormone-Sensitive Prostate Cancer
- Research Summaries
  Explore
  Clinical Edge Journal Scan
- Roundtables
- CE/CME
- Submission Guidelines
- Subscribe to Federal Practitioner
- Treatment of Veterans With Metastatic Hormone-Sensitive Prostate Cancer